Serum Pyridoxal 5'-Phosphate and Pyridoxic Acid Ratio Index with Prognosis of Colorectal Cancer: A Prospective Cohort Study.

Autor: Li X; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China., Xu L; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China., Ou QJ; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Xu H; Chronic Noncommunicable Disease Prevention and Control Department, Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China., Chen YY; Chronic Noncommunicable Disease Prevention and Control Department, Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, China., Fang YJ; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Zhang CX; Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.
Jazyk: angličtina
Zdroj: Nutrients [Nutrients] 2024 Oct 29; Vol. 16 (21). Date of Electronic Publication: 2024 Oct 29.
DOI: 10.3390/nu16213685
Abstrakt: Background: Studies on the association between serum vitamin B 6 status and colorectal cancer prognosis are limited and have yielded inconsistent results. This study investigated the association of pyridoxal 5'-phosphate (PLP) and pyridoxic acid ratio (PAr) index with colorectal cancer survival.
Methods: A total of 1286 colorectal cancer patients diagnosed since 2010 were selected from the Guangdong Colorectal Cancer Cohort study. Serum levels of PLP, pyridoxal, and 4-pyridoxic acid were measured using ultra-high-performance liquid chromatography-tandem mass spectrometry. The study followed overall mortality and colorectal cancer-specific mortality until December 2023. Multivariable Cox proportional hazards regression models were applied to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs). Restricted cubic spline and stratified analysis were performed.
Results: During a median follow-up of 77.36 months, 331 deaths were recorded, with 293 specifically attributed to colorectal cancer. Higher PLP levels were associated with a longer overall survival (HR Q4 vs. Q1 , 0.63; 95% CI: 0.46, 0.87; p for trend = 0.008) and colorectal cancer-specific survival (HR Q4 vs. Q1 , 0.62; 95% CI: 0.44, 0.87; p for trend = 0.006). Non-linear associations were observed between serum PLP and overall and colorectal cancer-specific survival ( p for non-linear < 0.05). However, PAr was not significantly associated with either overall survival (HR Q4 vs. Q1 , 1.03; 95% CI: 0.75, 1.41) or colorectal cancer-specific survival (HR Q4 vs. Q1 , 1.01; 95% CI: 0.72, 1.42). The association between serum PLP and both overall survival and colorectal cancer-specific survival ( p for interaction < 0.05) varied by alcohol drinking status.
Conclusions: Higher serum PLP levels, but not PAr, may be associated with improved overall and colorectal cancer-specific survival.
Databáze: MEDLINE
Externí odkaz: